Observational studyBMC cardiovascular disorders2025
Glycemic variability and postoperative mortality following cardiac surgery: evidence from a real-world ICU cohort.
Observational study in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modifiable Perioperative Practices for the Prevention of Postoperative Complications After Cardiac Surgery: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Cardiovascular Entropy and Mortality Prediction in Hemodialysis Patients.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlycemic variability (GV) may capture peri-operative metabolic instability more sensitively than absolute glucose levels, but its prognostic value after major cardiac surgery remains uncertain.
methodsWe retrospectively analyzed 2,943 ICU patients from the MIMIC-IV database who underwent coronary artery bypass grafting or valve surgery. GV was defined as the coefficient of variation of glucose during ICU stay. Primary outcome was 30-day all-cause mortality, with 90- and 360-day mortality as secondary endpoints. Missing covariates (< 20%) were multiply imputed with CART. Multivariable Cox regression, restricted cubic splines, and inverse probability of treatment weighting (IPTW) were applied. Subgroup analyses with interaction testing were conducted. Discriminatory performance was assessed by ROC curves, and nine machine learning models were benchmarked with LASSO-based feature selection and cross-validation.
resultsHigher GV was consistently associated with elevated mortality risk. In fully adjusted analyses, patients in the highest vs. lowest quartile had hazard ratios of 6.72 (95%CI 1.89-23.93) for 30-day, 2.46 (1.31-4.59) for 90-day, and 2.19 (1.44-3.32) for 360-day mortality. Associations appeared linear, remained robust after IPTW, and were confirmed in sensitivity analyses. No significant interactions were detected across clinical subgroups. GV alone showed fair discrimination for 30-day mortality (AUC 0.686), whereas the XGBoost model incorporating perioperative variables achieved the highest discrimination (AUC 0.845). SHAP analysis indicated GV contributed incremental prognostic information but was not the leading predictor.
conclusionAmong ICU patients undergoing cardiac surgery, greater GV was independently associated with higher short- and long-term mortality. GV may serve as a complementary marker to established clinical predictors for postoperative risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.